Browse Studies — Arctuva

Observational

A Post-Market, Prospective, Randomized, Controlled, Multicenter International Study to Assess the Safety of the Temporarily Implanted Nitinol Device (iTind) Compared to the UroLift® System in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)

The study objective is to evaluate the efficacy and safety of the iTind device compared to UroLift.

Benign Prostatic Hyperplasia (BPH)

Estimated

~$10 – $8,750

Olympus Corporation of the AmericasNCT04757116

The FLOW Registry: Functional and Longitudinal Outcomes With Waterjet Ablation

The purpose of this study is to create a database and prospective registry for data collection on patients with benign prostatic hyperplasia undergoing Aquabla…

Benign Prostatic Hyperplasia (BPH)

Estimated

~$10 – $750

University of ChicagoNCT07430423

In-Office Transperineal Laser Ablation (TPLA) as a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia (BPH) After Minimally Invasive Surgical Therapies (MIST)

Benign prostatic hyperplasia (BPH) is a common condition affecting aging men, often leading to lower urinary tract symptoms (LUTS). While Minimally Invasive Su…

Benign Prostatic Hyperplasia (BPH)

Estimated

~$10 – $750

The Cleveland ClinicNCT07016620

Phase 2

Effects of TNF Blockade on Human BPH/LUTS

Specific Aim 1. To evaluate the efficacy of TNF antagonist action in BPH/LUTS Specific Aim 2. Define the consequences of TNF antagonist therapy on prostate tis…

Benign Prostatic Hyperplasia (BPH)

Estimated

~$10 – $7,500

Endeavor HealthNCT06062875